IPO: Genenta Science S.p.A. Date: 15 December 2021

Symbol: GNTA
Industry: Biotechnology
Exchange: NASDAQ
IPO Price Low: $10.5
IPO Price High: $12.5

Genenta Science is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors. We have developed a novel biologic platform which involves the ex-vivo gene transfer of a therapeutic candidate into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages (Tie2 Expressing Monocytes – TEMs). Our technology is designed to turn TEMs, which normally have an affinity for and travel to tumors, into a “Trojan Horse” to counteract cancer progression and to prevent tumor relapse. Our technology is not target dependent, and therefore we believe it can be used as a treatment for a broad variety of cancers. Our lead product candidate, Temferon, was developed using our platform and carries an interferon-alpha (IFN-α) payload. Because Temferon delivers the IFN-α payload directly to the tumor, we believe it will demonstrate clinical activity without the side effect profile of systemic delivery of IFN-α. We are currently conducting a Phase 1/2a dose-escalation clinical trial with Temferon in newly diagnosed uMGMT-GBM patients in Italy. We anticipate completing patient enrollment and treatment by the second quarter of 2022.

Shares Offered: 2400000
Shares Outstanding: 18152714
Market Cap: 208756211

How to buy Genenta Science S.p.A. stock

For more information on the Genenta Science S.p.A. IPO please sign up using the form opposite.

IPO Exchange is dedicated to providing accurate information to help you make the best investment decisions and expand your portfolio.

Get more details on how you can invest in Genenta Science S.p.A. by signing up below.